The efficacy and safety of Crataegus extract WS® 1442 in patients with heart failure: The SPICE trial

[1]  J. D. White,et al.  Encyclopedia of Dietary Supplements , 2010 .

[2]  R. Schwinger,et al.  Crataegus Special Extract WS® 1442 Induces an Endothelium-Dependent, NO-mediated Vasorelaxation via eNOS-Phosphorylation at Serine 1177 , 2006, Cardiovascular Drugs and Therapy.

[3]  E. Ernst,et al.  Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. , 2003, The American journal of medicine.

[4]  S. Goldstein.  Beta blockers as cardioprotective agents: Part II--Focus on prevention of sudden cardiac death. , 2002, The American journal of managed care.

[5]  M. Tauchert.  Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. , 2002, American heart journal.

[6]  M. Tendera,et al.  Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE) — rationale, study design and study protocol , 2000, European journal of heart failure.

[7]  R. Schwinger,et al.  Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. , 2000, Journal of cardiovascular pharmacology.

[8]  O. Frankenberger,et al.  Beta-blockers and amiodarone for the primary prevention of sudden cardiac death , 1999, Current cardiology reports.

[9]  W J Shih,et al.  Modifying the design of ongoing trials without unblinding. , 1998, Statistics in medicine.

[10]  E. Koch,et al.  [In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms]. , 1997, Arzneimittel-Forschung.

[11]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[12]  W. Linke,et al.  Crataegus extract prolongs action potential duration in guinea-pig papillary muscle. , 1996, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[13]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[14]  W. Klaus,et al.  [Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart]. , 1995, Arzneimittel-Forschung.

[15]  H. Kammermeier,et al.  Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. , 1995, Arzneimittel-Forschung.

[16]  M. Gheorghiade,et al.  WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS , 2010 .

[17]  M. Kendall,et al.  Sudden cardiac death and the potential role of beta-adrenoceptor-blocking drugs. , 1993, Postgraduate medical journal.

[18]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[19]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[20]  H. Herrmann,et al.  Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. , 1990, Circulation.

[21]  H. Ikram,et al.  Xamoterol in severe heart failure , 1990, The Lancet.

[22]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[23]  J. Haybittle,et al.  Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.

[24]  M. Rich,et al.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. , 2006, European heart journal.

[25]  E. Ernst,et al.  Adverse-Event Profile of Crataegus Spp. , 2006, Drug safety.

[26]  G. Zapfe jun.  Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. , 2001, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[27]  G. Zapfe.  Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. , 2001 .

[28]  J. Siegrist,et al.  CRATAEGUS-SPEZIALEXTRAKT WS 1442 : OBJEKTIVER WIRKSAMKEITSNACHWEIS BEI PATIENTEN MIT HERZINSUFFIZIENZ (NYHA II) , 1996 .

[29]  M. Gheorghiade,et al.  Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. , 1993, The New England journal of medicine.

[30]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.